Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics
CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Development Stage:
- Early-stage
- In vitro data available
Related Invention(s):
E-158-2013-2
E-167-2013-0
E-196-2013-0
E-203-2013-0
E-474-2013-0
Inventors:
Conrad Quinn (CDC) ➽ more inventions...
Anne Boyer (CDC) ➽ more inventions...
Jason Goldstein (CDC) ➽ more inventions...
Dennis Bagarozzi (CDC) ➽ more inventions...
Intellectual Property:
US Application No. 61/699,738
PCT Application No. PCT/US2013/059179
US Application No. 14/427,329
Publications:
Boyer AE, et al. PMID 17929949
Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518
OTT Reference No: E-210-2013-0
Updated: Mar 3, 2017